Spondylarthropathies
19
3
4
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
5.3%
1 terminated out of 19 trials
90.0%
+3.5% vs benchmark
32%
6 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (19)
Evolution of Intestinal Microbiota in Patients With Juvenile Spondylarthropathy According to Typology of Treatment
Molecular Inflammation Board at the Center for Personalized Medicine
Assessing Pain by the painDETECT Questionnaire (PDQ)
Core Stabilization Training in Juvenile Spondyloarthropathy
Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital
Clinical and Dermoscopic Comparison of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriasis Patients' Nails
Chronic Inflammatory Disease, Lifestyle and Treatment Response
Chronic Inflammatory Disease, Lifestyle and Risk of Disease
Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis
Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening?
Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis
Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis
A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis
Seronegative Oligoarthritis of the Knee Study (SOKS)
Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF
Methotrexate in the Treatment of Axial Spondyloarthritis
Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies
TNFalfa Blocking Treatment of Spondylarthropathies